Browsing Tag
San Diego
39 posts
LivsMed completes $94m KOSDAQ IPO, eyes US entry and robotic expansion
LivsMed raised $94M in Korea’s largest 2025 IPO to fund global expansion. Find out how it plans to challenge surgical incumbents with its platform strategy.
Can NeoVolta’s Neubau Energy deal make modular home batteries the next big clean-tech revolution?
NeoVolta (NASDAQ: NEOV) acquires Neubau Energy assets to cut installation time and boost margins. Learn how this move could reshape home battery storage.
From cannabis to labs: Innovative Industrial Properties’ $105m IQHQ bet could reshape REIT diversification
Innovative Industrial Properties’ $105M IQHQ investment signals a REIT pivot to life-science real estate with high-yield structure and upside optionality.
Why Jack in the Box’s Burger Week could be its biggest promotion of 2025
Jack in the Box rolls out $5 Smashed Jacks and bonus cheeseburger deals all week—find out what’s behind the Burger Week push now!
Why MedImpact’s brand overhaul matters as U.S. payers demand lower drug costs and more control
MedImpact unveils a refreshed identity to emphasize modular healthcare solutions, digital innovation, and payer empowerment—read the full analysis now.
Disney Cruise Line charts bold expansion with new California and Texas sailings for 2026–2027
Disney Cruise Line expands with new 2026–2027 sailings from San Diego and Galveston, boosting West Coast and Texas cruise options.
Private jet crashes into San Diego’s Murphy Canyon at 3:45 a.m., killing all onboard and setting homes ablaze
Fatal jet crash in San Diego’s Murphy Canyon sets multiple homes on fire; FAA and NTSB launch investigation into cause and flight conditions.
Qualcomm Q2 FY2025 results: Automotive surge, share buybacks drive resilient performance amid trade pressures
Explore how Qualcomm’s Q2 FY25 earnings reflect strategic gains in automotive and IoT, capital returns, and evolving stock sentiment amid trade uncertainty.
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.
AI just got personal: Illumina and Tempus team up to make DNA testing part of every doctor’s visit
Find out how Illumina and Tempus are transforming healthcare with AI-driven genomic tools to advance precision medicine across cancer, cardiology, and more.